LOS ANGELES(Reuters) - Gilead Sciences Inc said 48-week data from a mid-stage trial of its closely watched four-medicine HIV pill known as the "Quad" show the drug works as well as the company's widely used Atripla three-drug tablet.
Analysts said the findings met expectations and the company's shares inched up by just a fraction.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!